Captive cell therapy test based on Bob Langer research is still terminated, the latest results will be issued next month

In July this year, Flagship Pioneering (FP) hatched package cell therapy Xinrui Sigilon Therapeutics Inc. (NASDAQ: SGTX) received the US FDA notification, suspended its patients with moderate or severe hemophilia for moderate or severe hemophilia Clinical trials of I / II.

The discontinuation of this test was due to a "a common treatment complication" in a patient. Prior to this, SIGILON has submitted a serious adverse event (SAE) report to the FDA and other regulators and suspend registration processes.

SIGILON launched in 2017 Robert Langer and Daniel Anderson laboratory in MIT. It is reported that SIGILON is listed in Nasdaque in December last year, and the market value is once more than 1 billion US dollars. At present, the company’s market value is only $ 122 million. And after the price of $ 18 in 18 US dollars, SIGILON is only slightly above $ 3.5 after the price of $ 48.

Robert Langer and MIT Daniel Anderson Laboratory research results based on Moderna Important Behind: SIGILON established the SIGILDED LIVING Therapeutics? (SLTX) technology platform, the engineering cell package is implanted into the patient. Its technical purpose is to protect the influence of the cells from the human immune system and prevent side effects. Therefore, some investors expressed concern for the test caused by complications due to complications.

Recently, SIGILON announced that after a patient in clinical study of only three people reported a serious adverse incident, the patient received laparoscopic surgery specified by the researcher to remove the implanted sphere. After inspection, it was determined that the sphere placed in the patient was already fibrilized, and the cells in the sphere no longer have vitality.

The patient accepted the highest dose in three individuals receiving the treatment, and there was a factor VIII antibody after the spherical implantation, which may be the cause of the patient to face uncontrolled bleeding risks.

Although the company surveyed the patient’s fibrotic sphere, all three patients participating in the SIG-001 test will continue to follow up in accordance with the research agreement. These findings may have an impact on the time of Patients in the I / II clinical trial of the SIG-005 I-type Polycharant Storage (MPS-1).

"Guaranteed patient safety is our primary task, we are collecting information to understand these observations," said Dr. Rogerio Vivaldi, President and CEO of Sigilon, "We will work closely with FDA, other regulators and company consultants to determine these Observation results on our project. "

Figure | Color scanning electron micrograph of blood clots (Source: The New York Times)

Hemophilia is a hereditary disease due to the lack of certain coagulation factors in the blood. The main manifestation of this disease is that it is difficult for blood and blood, and traditional therapy is long-term infusion condensation factor VIII.

Sigilon developed SIG-001 Hemophilia Type Tytopathic, by encapsulating cells that produce coagulation factor VIII into a semi-permeable protective film and implanted into a patient, while producing Caggered Factor VIII (FVIII) Free from an immune system attack and prevent scar tissue around it.

The SIGILON product line is mainly for three types of disease treatment: rare blood disease, lysosome disease and endocrine and other chronic diseases. It is to be explained that SIG-001 is the only major candidate drug that the company enters the clinical stage. If the test cannot be recovered, then SIGILON’s main push line will become two lysosomes that are currently undergoing clinical test. therapy.

Figure SIGILON R & D line (Source: SIGILON)

It is still unclear whether treatment has led to this adverse reaction incident, and the company spokesperson Brandon Hagen refused to express comments after the press release. SIGILON said in its published message, the results will be reviewed and evaluated in the SIG-001 Security Review Committee on next month.

Reference:

-End-

Bihui "The Innovative Application of Life Science Qihai Tracking Biotechnology" series audio program officially launched, we will take you to explore more interesting life science industry!

1 day sell 73,000 pieces, how to rise in the face and explode?

Weekly TOP2 "whiten mask", a total of 34.2W single last week, the live sales volume of this item accounts for 100%, and only 1 hot exclusive person is a live broadcast that drives the sales of goods?

In the "whiten mask" nearly 30 days, the sales volume reached 130,000, of which the sales of high sales came from the "1-meter film buoyancy directly grabbed" released by the master’s "best actor", estimated sales of 63,000 sales, sales of 2.51,000.

The live broadcast also has a variety of masks. This "whiten mask" explains more than 17 hours, more than 90% of the time is explaining this product, indicating that this is the main community. It is worth mentioning that in addition to the single product is fast and explosive, the master "best actor" has also passed through the live broadcast of 150,000 in the nearly 30 days, then what is the live broadcast, it can make the trumpet can quickly suck the powder and bring the goods ?

On-site packing mask form, stimulating explosion

Check out the recent live broadcast, found that the live broadcast between the product whitening spots, the live broadcast scene is mainly the form of on-site packaging. After shooting a few boxes in the public block message, the anchor will pack it according to the number of boxes, and read the ID and quantity of the purchase of users in real time. For example, "User XXX 3 box package shipments" "User XXX 5 box package delivery", and Pack the goods directly.

In this way, the live broadcast of the package is in the form of a broadcaster who is unwilling to look, not only can directly show the product, but also packages through the site, the user has more expensive delivery, stimulating the user’s passion.

Comparative retail price, highlight live promotions, let users feel cheap

In the live broadcast, the retail price of 268 yuan displayed on the show is displayed, and the comparison can highlight the super high preferential strength of 3.98 yuan in the live broadcast; at the same time, the swings of the bulk between the bulk between the lives are mostly "five boxes" "ten boxes", It is very good to stimulate users to buy multiple items and improve live GMV.

Especially with the arrival of autumn and winter, people have increased the demand for moisturizing, the consumption demand such as mask, emulsions, and the recent follow-up of such goods.

So, how do we find the promotion of the "mask" potential live broadcast?

Potential broadcast master single GMV over 2 million, skin care preheating video precision drainage

Related merchandise, goods data, broadcast master information, live information, and audience portrait screening, see the live hot sale, synchronous comparison live online number, sales, etc.

Skin care video preheating, draining audience more accurate

At the same time, we see the "Source of Live Traffic] It can be seen that with the increase of live time, video promotion has gradually improved, and finally 46% of the audience comes from video drainage, and the drainage exceeds 56,000.

So what is the video to the live broadcast?

We have viewed a few videos with high exposure during the live broadcast. It is mainly based on skin care dry goods. Most of the foreword is "I like …"

At the same time, nearly half of the live broadcasts are over 41 years old, and they are the audience of anti-aging products. It can be seen that the audience of video drafting into live broadcast is very precise, so the bulk transfer is high, the sales conversion rate is as high as 4.28%.